In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly's Transparency Strategy

Executive Summary

Lilly sees its own credibility problem, and the industry's, as a major financial challenge--compromising approvals, marketing claims and pricing. It also contends its solution, providing far more information about its products through its marketing and R&D organizations, provides a solution for the industry as a whole. But as it's been rolled out so far, the strategy will disproportionately benefit Lilly.

You may also be interested in...



Lilly Stands Firm Against Florida Price Negotiations

Lilly turned its back on Florida's call for supplemental rebates on Zyprexa knowing that it was protected by the new Medicare law. The company eventually reached a deal with the state that allows for price flexibility and supports longer use of the drug. Manufacturers with drugs categorized under Medicare's six protected drug classes could do the same.

Lilly Stands Firm Against Florida Price Negotiations

Lilly turned its back on Florida's call for supplemental rebates on Zyprexa knowing that it was protected by the new Medicare law. The company eventually reached a deal with the state that allows for price flexibility and supports longer use of the drug. Manufacturers with drugs categorized under Medicare's six protected drug classes could do the same.

Message Problems: One Key Lesson from the Cox-2 Advisory Panel

As important as the news that came out of the Cox-2 advisory panel hearings was the subtext: the industry's increasing loss of control over its marketing messages.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel